Alpha emitter radium-223 in patients with metastatic castration-resistant prostate cancer: A cost-utility analysis
Objective: To assess the cost effectiveness of radium-223 dichloride for patients with metastatic castration-resistant prostate cancer (mCRPC) in China.Materials and methods: A Markov model was developed to estimate the long-term health and economic outcomes of radium-223 plus best standard care (BS...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.1003483/full |
| _version_ | 1798028977668882432 |
|---|---|
| author | Xiaohui Zeng Qiao Liu Chongqing Tan Xiaomin Wan Yunhua Wang Xiaowei Ma |
| author_facet | Xiaohui Zeng Qiao Liu Chongqing Tan Xiaomin Wan Yunhua Wang Xiaowei Ma |
| author_sort | Xiaohui Zeng |
| collection | DOAJ |
| description | Objective: To assess the cost effectiveness of radium-223 dichloride for patients with metastatic castration-resistant prostate cancer (mCRPC) in China.Materials and methods: A Markov model was developed to estimate the long-term health and economic outcomes of radium-223 plus best standard care (BSC) treatment and BSC only for bone mCRPC patients over a lifetime horizon. The patients and interventions were modeled according to the ALSYMPCA trial. Costs were collected from a Chinese health system perspective. Utility values were derived from the published literature. The base-case model results were quality-adjusted life year (QALY), total cost, and incremental cost-utility ratio (ICUR). Uncertainty analyses were performed to assess the robustness of our conclusions.Results: Compared with the BSC arm, radium-223 achieved an excess 0.344 QALYs with an incremental cost of $29,459, resulting in an ICUR of $85,647 per QALY. The probability of Ra-223 being cost effective for the patients with bone mCRPC was sharply low (<0.5%) at a willingness-to-pay threshold of $38,136/QALY. Uncertainty analyses revealed that the model is robust to all the input parameters.Conclusion: Radium-223 is unlikely to be cost effective in patients with bone mCRPC at the current WTP threshold, from a Chinese health system perspective. In affluent areas with a high per-capita GDP, radium-223 therapy may be cost effective. |
| first_indexed | 2024-04-11T19:18:00Z |
| format | Article |
| id | doaj.art-9e140024282e4fb48ac1e68fd1c06cd9 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-11T19:18:00Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-9e140024282e4fb48ac1e68fd1c06cd92022-12-22T04:07:24ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-10-011310.3389/fphar.2022.10034831003483Alpha emitter radium-223 in patients with metastatic castration-resistant prostate cancer: A cost-utility analysisXiaohui Zeng0Qiao Liu1Chongqing Tan2Xiaomin Wan3Yunhua Wang4Xiaowei Ma5Department of Nuclear Medicine/PET Image Center, The Second Xiangya Hospital of Central South University, Changsha, ChinaDepartment of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, ChinaDepartment of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, ChinaDepartment of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, ChinaDepartment of Nuclear Medicine/PET Image Center, The Second Xiangya Hospital of Central South University, Changsha, ChinaDepartment of Nuclear Medicine/PET Image Center, The Second Xiangya Hospital of Central South University, Changsha, ChinaObjective: To assess the cost effectiveness of radium-223 dichloride for patients with metastatic castration-resistant prostate cancer (mCRPC) in China.Materials and methods: A Markov model was developed to estimate the long-term health and economic outcomes of radium-223 plus best standard care (BSC) treatment and BSC only for bone mCRPC patients over a lifetime horizon. The patients and interventions were modeled according to the ALSYMPCA trial. Costs were collected from a Chinese health system perspective. Utility values were derived from the published literature. The base-case model results were quality-adjusted life year (QALY), total cost, and incremental cost-utility ratio (ICUR). Uncertainty analyses were performed to assess the robustness of our conclusions.Results: Compared with the BSC arm, radium-223 achieved an excess 0.344 QALYs with an incremental cost of $29,459, resulting in an ICUR of $85,647 per QALY. The probability of Ra-223 being cost effective for the patients with bone mCRPC was sharply low (<0.5%) at a willingness-to-pay threshold of $38,136/QALY. Uncertainty analyses revealed that the model is robust to all the input parameters.Conclusion: Radium-223 is unlikely to be cost effective in patients with bone mCRPC at the current WTP threshold, from a Chinese health system perspective. In affluent areas with a high per-capita GDP, radium-223 therapy may be cost effective.https://www.frontiersin.org/articles/10.3389/fphar.2022.1003483/fullcost effectivenessradium-223metastatic castration-resistant prostate cancerQALYChina |
| spellingShingle | Xiaohui Zeng Qiao Liu Chongqing Tan Xiaomin Wan Yunhua Wang Xiaowei Ma Alpha emitter radium-223 in patients with metastatic castration-resistant prostate cancer: A cost-utility analysis Frontiers in Pharmacology cost effectiveness radium-223 metastatic castration-resistant prostate cancer QALY China |
| title | Alpha emitter radium-223 in patients with metastatic castration-resistant prostate cancer: A cost-utility analysis |
| title_full | Alpha emitter radium-223 in patients with metastatic castration-resistant prostate cancer: A cost-utility analysis |
| title_fullStr | Alpha emitter radium-223 in patients with metastatic castration-resistant prostate cancer: A cost-utility analysis |
| title_full_unstemmed | Alpha emitter radium-223 in patients with metastatic castration-resistant prostate cancer: A cost-utility analysis |
| title_short | Alpha emitter radium-223 in patients with metastatic castration-resistant prostate cancer: A cost-utility analysis |
| title_sort | alpha emitter radium 223 in patients with metastatic castration resistant prostate cancer a cost utility analysis |
| topic | cost effectiveness radium-223 metastatic castration-resistant prostate cancer QALY China |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.1003483/full |
| work_keys_str_mv | AT xiaohuizeng alphaemitterradium223inpatientswithmetastaticcastrationresistantprostatecanceracostutilityanalysis AT qiaoliu alphaemitterradium223inpatientswithmetastaticcastrationresistantprostatecanceracostutilityanalysis AT chongqingtan alphaemitterradium223inpatientswithmetastaticcastrationresistantprostatecanceracostutilityanalysis AT xiaominwan alphaemitterradium223inpatientswithmetastaticcastrationresistantprostatecanceracostutilityanalysis AT yunhuawang alphaemitterradium223inpatientswithmetastaticcastrationresistantprostatecanceracostutilityanalysis AT xiaoweima alphaemitterradium223inpatientswithmetastaticcastrationresistantprostatecanceracostutilityanalysis |